Long-term safety trial for teens with schizophrenia or autism irritability
Treatments studied
Part of Mental health clinical trials.
This trial looks at the long-term safety of KarXT, a medication for schizophrenia, and KarX-EC for irritability related to autism in teenagers. It is for teens who have already completed the main part of a previous study without serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already finished the main 8-week phase of one of the earlier studies (CN0120020, CN0120044, or CN0120045).
- You should not have had a serious side effect that would make this trial unsafe.
- You cannot have a high risk of harming yourself or others, or have recent suicidal thoughts or behaviors.
- You must not have very high blood pressure (stage 2 hypertension).
- Other medical conditions that could make the trial unsafe will be checked by the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine, KarXT, can safely and effectively treat schizophrenia in adolescents. It may help teenagers who have active symptoms like hallucinations or disorganized thinking.
This trial tests a new injectable form of KarXT for schizophrenia. It aims to see if the medicine is safe, tolerable, and how it works in the body.
This study tests a new medicine (KarXT) for schizophrenia, focusing on how it affects urological (bladder and urinary) safety. You'll stop your current antipsychotic and take the study drug to see if it works well and is safe for your urinary system.
This trial looks at how well KarXT works and what side effects it might have when people with schizophrenia switch to it from their current antipsychotic medication. It may be an option for those who have started KarXT recently or who plan to switch from their current treatment.
This trial tests a new medication called KarXT for people with schizophrenia who are currently having a psychotic episode. It is for Japanese adults who have had schizophrenia before and are not in their first episode.
This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.